We are enclosing herewith copy of Unaudited Financial Results for the quarter ended on 31st December, 2025 alongwith Limited Review Report thereon
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Denis Chem Lab, a manufacturer of parenteral/transfusion solutions, posted Q3 FY26 revenue from operations of Rs. 4,551.83 lakh, up about 6% from Rs. 4,284.13 lakh in Q3 FY25. Net profit jumped to Rs. 332.16 lakh from Rs. 176.14 lakh a year ago, nearly doubling year-on-year, helped by lower other expenses and favourable inventory adjustments. EPS for the quarter rose to Rs. 2.39 from Rs. 1.27. For the 9 months ended December 2025, revenue was Rs. 13,496.55 lakh (vs Rs. 13,191.63 lakh) and profit was Rs. 800.92 lakh (vs Rs. 736.83 lakh), with EPS of Rs. 5.77. The statutory auditor issued an unmodified (clean) limited review opinion, and the company has zero financial indebtedness with no related party transactions or audit qualifications.
Strong Q3 earnings beat with a near-doubling of profit signal healthy operating leverage and improved cost efficiency, which is positive for shareholders. The clean audit report, debt-free balance sheet and steady top-line growth make this a reassuring result, though the cumulative 9-month profit growth of around 9% is more modest.